NTrans Technologies receives a €1.5M grant under the Horizon 2020 SME instrument programme to advance its iTOP Technology.
NTrans Technologies today announced it has been awarded a prestigious, €1.5M EU SME instrument grant. NTrans Technologies is a spin-off company that emerged from research of the Hubrecht Institute. The company is based on a proprietary technology (iTOP), which allows the intracellular delivery of therapeutic proteins in a wide range of cell types and tissues.
Marco de Boer, CEO of NTrans Technologies BV, commented: “We are honored that the European Commission recognized the tremendous potential of our iTOP Technology delivery platform”.
Supported by the 1.5 million euro SME instrument grant funding, NTrans Technologies will have the opportunity to further develop and market its iTOP Technology for research applications, and by this accelerate the growth of the company.
About NTrans Technologies
NTrans Technologies BV was founded in 2015 based on a proprietary platform technology for the intracellular delivery of bioactive molecules developed at the Hubrecht Institute of the Royal Netherlands Academy of Arts and Sciences. The iTOP intracellular delivery technology is based on a combination of small molecule compounds which forces the uptake of large gulps of extracellular fluid (containing the bioactive molecules) by the cell (D’Astolfo et al. 2015, Cell 161: 674-690). Once inside, the vesicles release their content into the cytoplasm, where the bioactive molecules (like gene editing systems) can exert their therapeutic action.
Our goal is to further support distribution and commercialization of the iTOP technology for the research community and to develop a therapeutic platform for iTOP based delivery of bioactive molecules. The NTrans mission is to translate the unique iTOP technology into revolutionary new therapies for the treatment of genetic diseases and cancer. For more information on NTrans Technologies please visit our website:
About SME instrument grant
The SME instrument grant is part of Horizon 2020, which is the largest EU Research and Innovation program ever. Provided with about €3 billion in funding over the period 2014-2020, the SME Instrument helps high-potential SMEs to develop groundbreaking innovative ideas for products, services or processes that are ready to face global market competition.
For more information, please visit: